The present invention relates to a biological sensor. More particular, the present invention relates to a biological sensor utilizing a field-effect transistor (FET).
A currently common single-protein measurement procedure in clinical diagnosis is immunoassay, in which monoclonal immunoglobulin or their antigen binding domains are used to bind antigens of interest. Among these assays, the enzyme-linked immunosorbent assay (ELISA) is the most widely used assay for the measurement of a single protein in solution. The ELISA experiment is typically conducted in a well plate of 96 or 384 wells, with a limit of sensitivity of about 1 pg/mL, a dynamic range of about 103 (corresponding to a range of about 0.1 ng/mL-about 100 ng/mL) and over several hours of experiment time. A microarray is fabricated by the immobilization of affinity probes (typically antibodies) in arrays at high spatial density on a solid substrate. Each probe is used to capture specific proteins and then the proteins are labeled using secondary antibodies carrying fluorescent, colorimetric or radioisotope signals. The concentration of antigens is quantified by measuring the fluorescent intensity, a detection method that is similar to DNA microarrays.
Different to label-based detection, the label-free detection measures the change in inherent properties caused by the molecular binding on the sensor surface, such as charge, mass, stress, or dielectric constant, etc. The label-free techniques not only eliminate laborious, time-consuming procedures for tagging fluorescent probes, but also enable the determination of reaction kinetics of biomolecular interaction in real-time. Among these developments, detection of biomolecular charges using nanowires is very attractive because it does not require sophisticated instrumentation, and offers high sensitivity and a broad detectable dynamic range. To date, most of antibody conjugation on nanowires is still conducted by pipette or microfluidic channels. The high cost of reproducibly manufacturing nanowires and the lack of reliable, high-throughput surface functionalization hinder the applications of nanowires to label-free detection for cancer diagnosis and point-of-care testing.
It is therefore desirable to find a cheaper and faster way of biomedical and chemical sensing that is suitable for clinical applications.
According to the present invention, a graphene biosensor comprises an electrically insulating substrate, a first metallic electrode and a second metallic electrode, the first and second metallic electrodes being mounted on the substrate, a single-layer graphene sheet in electrical contact with and connecting the first and second metallic electrodes. The graphene sheet comprises perforations with edges having a total edge length. The added edge length enhances the reactivity of the graphene sheet with biomolecules.
According to one aspect of the invention, the perforations are formed by holes in the graphene sheet or gaps between graphene strips.
According to one aspect of the invention, the holes or gaps have a diameter smaller than about 10 μm, preferably smaller than 10 μm.
According to one aspect of the invention, the holes or gaps have a diameter smaller than about 5 μm, preferably smaller than 5 μm.
According to one aspect of the invention, the perforations are arranged in a substantially regular pattern at a distance from each other smaller than about 5 μm, preferably smaller than 5 μm.
According to one aspect of the invention, the perforations are arranged in a substantially regular pattern at a distance from each other smaller than about 1 μm, preferably smaller than 1 μm.
According to one aspect of the invention, the total edge length relative to the graphene sheet area has an edge-to-area ratio greater than about 0.1 μm−1, preferably greater than 0.1 μm−1.
According to one aspect of the invention, the edge-to-area ratio is greater than about 0.5 μm−1, preferably greater than 0.5 μm−1.
According to one aspect of the invention, the edge-to-area ratio is greater than about 0.7 μm−1, preferably greater than 0.7 μm−1.
According to one aspect of the invention, the biosensor further comprises a reference electrode configured to be supplied with a variable gate voltage and configured to be in indirect contact with the graphene sheet via a fluid connection.
According to one aspect of the invention, graphene sheet may comprise immobilized affinity probes configured to attach specific molecules to the graphene sheet. The affinity probes may be antibodies configured to attach specific antigens to the graphene sheet. These specific antibodies allow for selective testing for biomarkers.
According to another aspect of the invention, the sensor may include an array of at least two graphene sheets including a first and a second graphene sheet. Several graphene sheets of the array may comprise affinity probes.
According to a further aspect of the invention, different affinity probes may be associated with different graphene sheets.
According to yet another aspect of the invention, at least one of the graphene sheets in the array may comprise immobilized affinity probes, and at least one of the graphene sheets may be free of any affinity probes.
According to one aspect of the invention, the sensor may be configured as an ion-sensitive field effect transistor (ISFET) for testing fluids. The sensor may be configured to measure a property of a liquid contacting the reference electrode, the source electrode, the drain electrode and the first graphene sheet, and the sensor may measure an electric current between the drain electrode and the source electrode during exposure to the liquid.
According to another aspect of the invention, the sensor may be calibrated to operate near the Dirac point of the conductance during exposure to the liquid.
In a further development of the invention, the ISFET may comprise a cavity and at least two ports in fluid communication with the cavity. The cavity may contain the graphene sheet and the set of electrodes, and the ports may be configured to supply the liquid to the cavity and to drain the liquid from the cavity.
According to a further aspect of the invention, for continuous measurement over a period of time, one of the at least two ports may be an inlet port for supplying the liquid to the cavity and the one of the at least two ports maybe an outlet port for draining the liquid from the cavity, and both inlet port and outlet port may be configured to be operated at the same time to allow a continuous flow of liquid through the cavity.
According to yet another aspect of the invention, the sensor may be configured to be mounted on a catheter of the type having a proximal end and a distal end, an electric connector disposed at the proximal end; and an electrical connection extending along the catheter and connecting the distal end to the electric connector. The sensor may be configured to be mounted on the distal end and to be connected to the electrical connection for in situ measurements. The graphene sheet of the sensor configured to be mounted on the tip of the catheter may also carry immobilized affinity probes configured to attach specific molecules to the graphene sheet.
Further details and benefits become apparent from the following description of various embodiments of the invention in connection with the attached drawings.
a through 3i schematically show assembly steps of an ISFET suitable for the analysis of liquids in accordance with one embodiment of the present invention;
a through 8d show steps of preparing a graphene sheet for detecting and identifying specific biomolecules in accordance with one embodiment of the present invention;
a through 14h show manufacturing steps of making a graphene sheet with edge defects according to one embodiment of the invention;
The appended drawings serve purely illustrative purposes and are not intended to limit the scope of the present invention.
The electrodes 102 and 104 are in direct electrical contact with the graphene sheet 10. A drain-source voltage Vds is applied between the source and drain electrodes 102 and 104, and a gate voltage VAg/AgCl is applied between the reference electrode 106 and the drain electrode 104. The reference electrode 106 is not in direct contact with the graphene sheet 10 and supplies the variable gate voltage to a water-based liquid, referenced as H2O, that is in contact with all three electrodes 102, 104, and 106, as well as the graphene sheet 10. Thus, in this embodiment, the electrode 106 is only in indirect contact with the graphene sheet 10 and with the other two electrodes 102 and 104 via the liquid. None of the electrodes 102-106 are in direct electrical contact with each other. The sensor 100 measures the conductance of the graphene sheet 10 by measuring an electric current between the electrodes 102 and 104 under varying gate voltages supplied by the reference electrode 106.
a through 3i show assembly steps for the manufacture of an ISFET similar to the embodiment of
For example, for larger graphene samples, a chemical vapor deposition (CVD) system can be applied to grow wafer-scale graphene. In the CVD method, a thin copper foil with a thickness of about 25 μm, preferably 25 μm, may first be thermally annealed at a high temperature ranging from about 900° C. to about 1000° C., preferably between 900° C. and 1000° C. The copper can subsequently be exposed to hydrocarbon environment in a CVD chamber exposed to a flow of methane (CH4). Preferred values for the conditions inside the CVD chamber are about 30 standard cubic centimeters per minute (about 30 sccm), preferably 30 sccm, for the flow of CH4, a pressure of about 500 mTorr, preferably 500 mTorr, and a temperature of about 1000° C., preferably 1000° C. Next, the graphene-covered copper substrate can be spin-coated with a polymer film. In the present example, the polymer is Poly(methyl methacrylate) (PMMA), a transparent thermoplastic with various uses, for example as a glass substitute or as photoresist for e-beam lithography. Subsequently, the copper foil can be etched as a sacrificial layer using FeCl3. Dissolving the PMMA film in Acetone results in a single graphene layer that can be transferred onto a wafer.
Once a graphene sheet 10 has been produced, a graphene sensor can be manufactured, for example through the steps illustrated in
As illustrated in
Then, according to
As illustrated in
Now referring to
Now referring to
Now referring to
Now referring to
As illustrated in
Experiments have shown that graphene containing a large number of impurities and structural defects exhibits a bad signal-to-noise ratio. Accordingly, it was believed that graphene with a highly regular structure is ideal for biosensors. Chemical vapor deposition has enabled the creation of such regular structures.
The sensor has the configuration of an ISFET (ion-sensitive field effect transistor), and the carrier concentration (conductance) can be modulated by the applied gate voltage and ionic groups in the solution. The graphene sheet 10 is a p-type semiconductor under the ambient conditions with holes constituting the charge carriers, where impurities can be partly attributed to adsorbed oxygen molecules or residues of photoresist. The point of minimum conductivity is called Dirac point, where charge carriers change from holes to electrons. When measuring drain-source current Id through substantially homogenous graphene sheet 10, the Dirac points are nearly indistinguishable for all pH values. As illustrated in
This behavior can be explained with the hydrophobic properties of homogenous graphene. The regular honeycomb structure resists electric polarization and will thus not react easily with polar biomolecules that may, for example, contain OH groups. It has been discovered that artificial, controlled edge defects in the otherwise highly regular graphene sheet structure enhance the reactivity of the graphene sheet 10.
a through 14h show steps in a process of creating edge defects in a highly regular graphene sheet according to one embodiment of the invention. A large graphene sheet 10 can be grown, for example by the CVD method using CH4 as reaction gas on a clean copper foil. Initially, a copper foil can be annealed for increased homogeneity and polished to obtain a surface even enough for creating a very regular honeycomb pattern of graphene. CH4 can be flown into the furnace at a rate of about 30 sccm, preferably 30 sccm, for about 30 minutes, preferably 30 minutes, at about 1000° C., preferably 1000° C., and the pressure can be controlled to be about 500 mTorr, preferably 500 mTorr. After deposition of the carbon on the copper foil, the copper foil can be removed via wet etching to dissolve the copper foil. This leaves a substantially pure graphene sheet that can be transferred onto a SiO2/Si substrate of about 300 nm thickness, preferably 300 nm, by stamping as described in connection with
a shows a small cutout of a graphene sheet 10. For simplicity, the substrate supporting the graphene sheet is not shown.
As shown in
As shown in
In the embodiment of
The edge-to-area ratio is calculated from the length of all holes 654 in an area of the graphene sheet 610 divided by the area. Other ranges of edge-to-area ratios can be obtained by changing the density, the shape, or the size of the holes 554 fabricated in the graphene sheet 610. Feasible edge-to-area ratios range from about 0.1 μm−1, preferably from 0.1 μm−1, to as high as is realizable within given technological and financial constraints. By using nanolithography, for example, much smaller holes can be produced at a much higher density so that edge-to-area ratios of greater than about 1 μm−1, preferably greater than 1 μm−1, can be produced. With the described electron beam lithography and oxygen plasma treatment, edge-to-area ratios of more than about 0.7 μm−1, preferably greater than 0.7 μm−1 are realistically producible.
Increased conductance is observed at the Dirac point for lower pH values, i.e. higher acidity. This increased conductance can be attributed to the increased number of negative-charged hydroxyl groups around graphene. The attached hydroxyl oxide acts as electron acceptor. Because the device is a p-type semiconductor, the charge carriers are holes, and the concentration of charge carriers increases with higher pH values. In comparison with
In this embodiment, the minimum carrier concentration in graphene is measured in a decimal order of magnitude of 1012 cm−2. Such low carrier concentration makes graphene a promising sensing material. The sensitivity to biomolecules is represented by the following equation:
Sensitivity=ΔG/G=Δn/n
where G represents the conductance of graphene and n represents the number of charge carriers of graphene.
It is evident, that a small number of charge carriers in the graphene, i.e. a low conductance, results in a higher sensitivity because a given change Δn in charge carriers makes a greater difference relative to the existing number of charge carriers.
For example, detection of single gas molecules has been demonstrated using micron-sized graphene without the need for nanolithography to scale down geometry. The high electron mobility (at least about 15000 cm2V−1s−1, preferably at least 15000 cm2V−1s−1 at room temperature) of graphene leads to low Johnson noise (thermal noise) and to a rapid signal transduction for chemical and biological sensing. It is therefore possible to measure the acidity of a liquid sample according the curve shown in
A graphene ISFET structured like the sensor 100 may also be used for label-free biomolecule detection. Several chemical reactions are available, covalent reactions and noncovalent reactions, such as p-p interaction, hydrophobic effects, and van der Waals forces.
According to one embodiment of the invention, the immobilization of affinity probes R on the graphene sheet can be facilitated by incorporating edge defects in the graphene sheet as shown in
After the graphene sheet 10 has been prepared for affinity to a specific biomolecule 138,
In analogy to
Under different settings, for example when the gate voltage is about 0.3 V, preferably 0.3 V, which is slightly above the Dirac point, the carriers in the graphene are electrons. The conductivity decreases with increased BSA concentration, where BSA is an electron acceptor. When the applied gate voltage is about −0.4 V, preferably −0.4 V, the graphene sheet 10 becomes metallic (high carrier concentration) and the carriers are holes. Although the conductance increases with increased BSA concentration, the sensor becomes less responsive. The graphene biosensor is more sensitive to the surface charges if working around the Dirac point, where the carrier concentration is at a minimum. Accordingly, the gate voltage can be calibrated to conduct the measurements near the Dirac point. Because the Dirac point moves to higher gate voltages as the concentration of BSA increases, the Dirac point allows a quantitative determination of the BSA concentration in the physiological solution.
The targeted, label-free detection of specific biomolecules opens a multitude of possibilities for the production of graphene-based protein microarrays and their use in the simultaneous detection of multiple biomolecule concentrations.
a through 9d give an illustrative schematic example of such a graphene-based microarray sensor 200. Illustrated in
The immobilized affinity probes attaching to different biomolecules allow a simultaneous quantitative measurement of different biomarkers, for example biomarkers associated with different types of cancer, in blood serum or tissue extraction. The molecular events in the protein microarray 200 are complex and form multi-step processes. Now referring to
The individual graphene sheets 210 function as field-effect transistor. When charged molecules (such as antigens) are adsorbed on one of the graphene sheets 210, the carrier concentration of the respective graphene sheet 210 is reduced or increased by the charges.
d illustrates a saturation curve indicative of biomolecules 238 attaching to affinity probes on one the graphene sheets 210.
Referring now to
In summary, graphene addresses the current bottleneck of label-free electrical detection by improving manufacturing cost, surface functionalization and response time. The advantages of graphene in biosensor design are evident.
Graphene is highly compatible with microfabrication techniques for device integration because of its planar structure. The surface area and geometry of graphene can be controlled using contact aligner and oxygen plasma.
Graphene is very efficient to detect antigens in extremely low concentration. Graphene is two-dimensional structure, and thus its entire surface is exposed to the solution. Using finite element analysis, it is estimated that the time for molecular binding is seconds for micron-sized graphene compared to hours for nanowires, assuming the concentration of about 10 fM, preferably 10 fM, a diffusivity of target proteins of about 10 μm2/s, preferably 10 μm2/s, a flow rate of about 10 μL/min, preferably 10 μL/min, reaction kinetics of about 106 M−1s−1, preferably 106 M−1s−1, and a binding site density of about 2×1012 sites/cm2, preferably 2×1012 sites/cm2. The rapid detection is significant for analyzing clinical samples, such as human blood or other body fluids, because the presence of proteolytic enzymes in the blood causes denature of proteins in a long run.
Graphene is easier to be functionalized than carbon nanowires. Because of its planar structure, various antibody molecular probes can be immobilized uniformly on the chemically-functionalized graphene using low-cost robotic spotting techniques.
Low-cost, wafer-scale, high-quality graphene has been grown using chemical vapor deposition. Compared to lithography-based silicon nanowires, the manufacturing cost of a graphene sensor is substantially lower because it does not require expensive nanolithography. Further, graphene can be transferred and integrated with polymer substrates for the applications such as flexible electronics and implantable microdevices.
While various embodiments for carrying out the invention have been described in detail, those familiar with the art to which this invention relates will recognize various alternative designs and embodiments for practicing the invention as defined by the following claims.
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/US12/25377 | 2/16/2012 | WO | 00 | 11/4/2013 |
Number | Date | Country | |
---|---|---|---|
61443474 | Feb 2011 | US |